8-K
filed May 7, 2024, 7:59 PM ET
CIK 0001444380
earnings
confidence high
sentiment positive
materiality 0.70
Nevro Q1 revenue $101.9M (+5.8%), net loss $35.8M; raises adjusted EBITDA guidance, promotes Christoforou to COO
NEVRO CORP
2024-Q1 EPS reported
-$0.70
revenue$101,899,000
- Q1 2024 worldwide revenue $101.9M, up 5.8% YoY; net loss from operations $35.8M; adjusted EBITDA loss $9.6M.
- FY2024 revenue guidance reaffirmed at $435–445M; adjusted EBITDA guidance raised to loss $5M to profit $2M.
- Additional restructuring steps announced to accelerate profitability and strengthen operations.
- Christofer Christoforou promoted to newly created COO role; he has been with Nevro for eight years.
- SI joint business: over 220 physicians trained on Nevro1™, one of three SI joint products.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
NEVRO CORP updated its full-year 2024 guidance (raised).
- Period
- full-year 2024
- Guidance
- raised
- Result
- guidance update
Exact text from the filing
reaffirming our revenue guidance of $435 million to $445 million for the full-year 2024
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
NEVRO CORP updated its full-year 2024 guidance (raised).
- Period
- full-year 2024
- Guidance
- raised
- Result
- guidance update
Exact text from the filing
raising our adjusted EBITDA guidance to a range of a loss of $5 million to positive $2 million
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
NEVRO CORP reported first quarter 2024 results: revenue $101.9 million, net income loss of $35.8 million.
- Period
- first quarter 2024
- Revenue
- $101.9 million
- Net income
- loss of $35.8 million
- Result
- reported results
Exact text from the filing
Worldwide revenue grew to $101.9 million, an increase of 5.8% as reported and 5.6% on a constant currency basis.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.